189 related articles for article (PubMed ID: 36213261)
1. A novel
Zuo Q; Yang W; Liu B; Yan D; Wang Z; Wang H; Deng W; Cao X; Yang J
Front Endocrinol (Lausanne); 2022; 13():1008800. PubMed ID: 36213261
[TBL] [Abstract][Full Text] [Related]
2. Defective O-glycosylation of novel FGF23 mutations in a Chinese family with hyperphosphatemic familial tumoral calcinosis.
Liu C; Pang Q; Jiang Y; Xia Y; Fang L; Wang O; Li M; Xing X; Gong Y; Xia W
Bone; 2020 Aug; 137():115401. PubMed ID: 32360901
[TBL] [Abstract][Full Text] [Related]
3. Hyperphosphatemic familial tumoral calcinosis secondary to fibroblast growth factor 23 (FGF23) mutation: a report of two affected families and review of the literature.
Chakhtoura M; Ramnitz MS; Khoury N; Nemer G; Shabb N; Abchee A; Berberi A; Hourani M; Collins M; Ichikawa S; El Hajj Fuleihan G
Osteoporos Int; 2018 Sep; 29(9):1987-2009. PubMed ID: 29923062
[TBL] [Abstract][Full Text] [Related]
4. Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.
Rafaelsen S; Johansson S; Ræder H; Bjerknes R
BMC Genet; 2014 Sep; 15():98. PubMed ID: 25249269
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.
Ramnitz MS; Gourh P; Goldbach-Mansky R; Wodajo F; Ichikawa S; Econs MJ; White KE; Molinolo A; Chen MY; Heller T; Del Rivero J; Seo-Mayer P; Arabshahi B; Jackson MB; Hatab S; McCarthy E; Guthrie LC; Brillante BA; Gafni RI; Collins MT
J Bone Miner Res; 2016 Oct; 31(10):1845-1854. PubMed ID: 27164190
[TBL] [Abstract][Full Text] [Related]
6. Congenital Hyperphosphatemic Conditions Caused by the Deficient Activity of FGF23.
Ito N; Fukumoto S
Calcif Tissue Int; 2021 Jan; 108(1):104-115. PubMed ID: 31965220
[TBL] [Abstract][Full Text] [Related]
7. FGF23-S129F mutant bypasses ER/Golgi to the circulation of hyperphosphatemic familial tumoral calcinosis patients.
Shawar SM; Ramadan AR; Ali BR; Alghamdi MA; John A; Hudaib FM
Bone; 2016 Dec; 93():187-195. PubMed ID: 26620085
[TBL] [Abstract][Full Text] [Related]
8. Dialysis as a Treatment Option for a Patient With Normal Kidney Function and Familial Tumoral Calcinosis Due to a Compound Heterozygous FGF23 Mutation.
Goldenstein PT; Neves PD; Balbo BE; Elias RM; Pereira AC; Onuchic LF; Jüppner H; Jorgetti V; Abensur H; Moysés RM
Am J Kidney Dis; 2018 Sep; 72(3):457-461. PubMed ID: 29548779
[TBL] [Abstract][Full Text] [Related]
9. Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies.
Roberts MS; Burbelo PD; Egli-Spichtig D; Perwad F; Romero CJ; Ichikawa S; Farrow E; Econs MJ; Guthrie LC; Collins MT; Gafni RI
J Clin Invest; 2018 Dec; 128(12):5368-5373. PubMed ID: 30226830
[TBL] [Abstract][Full Text] [Related]
10. Hyperphosphatemic Familial Tumoral Calcinosis in Two Siblings with a Novel Mutation in
Kışla Ekinci RM; Gürbüz F; Balcı S; Bişgin A; Taştan M; Yüksel B; Yılmaz M
J Clin Res Pediatr Endocrinol; 2019 Feb; 11(1):94-99. PubMed ID: 30015621
[TBL] [Abstract][Full Text] [Related]
11. Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.
Folsom LJ; Imel EA
Curr Osteoporos Rep; 2015 Apr; 13(2):78-87. PubMed ID: 25656441
[TBL] [Abstract][Full Text] [Related]
12. Root anomalies and dentin dysplasia in autosomal recessive hyperphosphatemic familial tumoral calcinosis (HFTC).
Vieira AR; Lee M; Vairo F; Loguercio Leite JC; Munerato MC; Visioli F; D'Ávila SR; Wang SK; Choi M; Simmer JP; Hu JC
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Dec; 120(6):e235-9. PubMed ID: 26337219
[TBL] [Abstract][Full Text] [Related]
13. Hyperphosphatemic Tumoral Calcinosis: Pathogenesis, Clinical Presentation, and Challenges in Management.
Boyce AM; Lee AE; Roszko KL; Gafni RI
Front Endocrinol (Lausanne); 2020; 11():293. PubMed ID: 32457699
[TBL] [Abstract][Full Text] [Related]
14. Severe vascular calcification and tumoral calcinosis in a family with hyperphosphatemia: a fibroblast growth factor 23 mutation identified by exome sequencing.
Shah A; Miller CJ; Nast CC; Adams MD; Truitt B; Tayek JA; Tong L; Mehtani P; Monteon F; Sedor JR; Clinkenbeard EL; White K; Mehrotra R; LaPage J; Dickson P; Adler SG; Iyengar SK
Nephrol Dial Transplant; 2014 Dec; 29(12):2235-43. PubMed ID: 25378588
[TBL] [Abstract][Full Text] [Related]
15. Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression.
Ichikawa S; Sorenson AH; Austin AM; Mackenzie DS; Fritz TA; Moh A; Hui SL; Econs MJ
Endocrinology; 2009 Jun; 150(6):2543-50. PubMed ID: 19213845
[TBL] [Abstract][Full Text] [Related]
16. A mouse with an N-Ethyl-N-nitrosourea (ENU) Induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosis.
Esapa CT; Head RA; Jeyabalan J; Evans H; Hough TA; Cheeseman MT; McNally EG; Carr AJ; Thomas GP; Brown MA; Croucher PI; Brown SD; Cox RD; Thakker RV
PLoS One; 2012; 7(8):e43205. PubMed ID: 22912827
[TBL] [Abstract][Full Text] [Related]
17. The Successful Treatment of Deep Soft-tissue Calcifications with Topical Sodium Thiosulphate and Acetazolamide in a Boy with Hyperphosphatemic Familial Tumoral Calcinosis due to a Novel Mutation in
Döneray H; Özden A; Gürbüz K
J Clin Res Pediatr Endocrinol; 2022 Jun; 14(2):239-243. PubMed ID: 33685073
[TBL] [Abstract][Full Text] [Related]
18. A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.
Dumitrescu CE; Kelly MH; Khosravi A; Hart TC; Brahim J; White KE; Farrow EG; Nathan MH; Murphey MD; Collins MT
Osteoporos Int; 2009 Jul; 20(7):1273-8. PubMed ID: 18982401
[TBL] [Abstract][Full Text] [Related]
19. Loss of the disease-associated glycosyltransferase Galnt3 alters Muc10 glycosylation and the composition of the oral microbiome.
Peluso G; Tian E; Abusleme L; Munemasa T; Mukaibo T; Ten Hagen KG
J Biol Chem; 2020 Jan; 295(5):1411-1425. PubMed ID: 31882545
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
